Repligen | RGEN - الأصول





الأصول تغيير تاريخ
Agilent USD 12.81B 86M 2025-12
Align Technology USD 6.31B 80.48M 2026-03
Bio Techne USD 2.55B 27.9M 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Bruker USD 6.13B 110.7M 2026-03
Charles River Laboratories USD 7.73B 594.89M 2026-03
Danaher USD 83.54B 80M 2026-03
Dentsply International USD 5.23B 200M 2026-03
General Electric Aerospace USD 128.45B 1.72B 2026-03
Henry Schein USD 11.3B 89M 2026-03
Illumina USD 6.56B 85M 2026-03
IQVIA Holdings USD 29.68B 269M 2026-03
Mettler Toledo International USD 3.67B 43.73M 2026-03
Myriad Genetics USD 673.7M 32.9M 2026-03
OraSure Technologies USD 379.17M 24M 2026-03
Pacific Biosciences Of California USD 782.36M 1.72M 2026-03
Pfizer USD 207.62B 542M 2026-03
Repligen USD 2.93B 18.93M 2026-03
Revvity USD 12B 171.82M 2026-03
Standard Biotools USD 639.11M 71.36M 2026-03
Thermo Fisher Scientific USD 113.28B 2.94B 2026-03
Waters USD 24.53B 19.45B 2026-03
West Pharmaceutical Services USD 4.11B 160.2M 2026-03